Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
remain the frontline standard of care for patients with EGFR-mutant non-small cell lung …
remain the frontline standard of care for patients with EGFR-mutant non-small cell lung …
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
Y Zhao, B Cheng, Z Chen, J Li, H Liang, Y Chen… - Critical Reviews in …, 2021 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are treatments
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …
A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients
B Biswas, N Ghadyalpatil, MV Krishna… - Indian Journal of …, 2017 - journals.lww.com
The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment of EGFR-mutant nonsmall cell lung cancer (NSCLC). These …
revolutionized the treatment of EGFR-mutant nonsmall cell lung cancer (NSCLC). These …
[HTML][HTML] Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have become the
cornerstone in the treatment of lung cancers that harbor EGFR mutations, but also play an …
cornerstone in the treatment of lung cancers that harbor EGFR mutations, but also play an …
Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non–small‐cell lung cancer patients: A network meta‐analysis
Z Wu, S Chen, X Du, Y Wu, X Xie - Journal of Clinical …, 2021 - Wiley Online Library
What is known and objective The efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR‐TKIs) in patients diagnosed with non–small‐cell lung cancer (NSCLC) has …
inhibitors (EGFR‐TKIs) in patients diagnosed with non–small‐cell lung cancer (NSCLC) has …
Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
JY Zhou, SY Liu, YL Wu - Expert Opinion on Drug Safety, 2020 - Taylor & Francis
Introduction: Lung cancer is the most prevalent malignant tumors worldwide. Over the past
decade, the emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
decade, the emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis
A Passaro, M Di Maio, E Del Signore, B Gori… - Clinical Lung Cancer, 2014 - Elsevier
Introduction Nonhematologic toxicities are frequently observed in patients receiving
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non …
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first-and second …
J Subramanian, AW Fernandes, F Laliberté, M Pavilack… - Lung Cancer, 2019 - Elsevier
Objectives Clinical trials with first-and second-generation epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) reported severe adverse events (SAEs) in 6%–49 …
tyrosine kinase inhibitors (EGFR-TKIs) reported severe adverse events (SAEs) in 6%–49 …
Efficacy of next-generation EGFR-TKIs in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials
YT Qi, Y Hou, LC Qi - Technology in Cancer Research & …, 2020 - journals.sagepub.com
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine
kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first …
kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first …
[HTML][HTML] Management strategies for adverse events associated with EGFR TKIs in non–small cell lung cancer
WH Vogel, P Jennifer - Journal of the Advanced Practitioner in …, 2016 - ncbi.nlm.nih.gov
New advances in the treatment of non–small cell lung cancer (NSCLC) have afforded
patients longer progression-free survival times, but these therapies are also associated with …
patients longer progression-free survival times, but these therapies are also associated with …
相关搜索
- receptor tyrosine kinase inhibitors
- growth factor kinase inhibitors
- cell lung cancer patients
- growth factor receptor tyrosine
- event profiles kinase inhibitors
- growth factor event profiles
- lung cancer toxicity profile
- lung cancer meta analysis
- event profiles receptor tyrosine
- management strategies adverse events
- expert consensus adverse events
- event profile meta analysis
- egfr tkis meta analysis
- egfr tkis cancer patients
- egfr tkis nonhematologic toxicities
- toxicity profile meta analysis